# Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

> **NCT01875874** · PHASE2 · TERMINATED · sponsor: **Vital Therapies, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Acute Liver Failure
- Fulminant Hepatic Failure
- Primary Graft Non-Function
- Surgically-Induced Liver Failure

## Interventions

- **BIOLOGICAL:** ELAD

## Key facts

- **NCT ID:** NCT01875874
- **Lead sponsor:** Vital Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2015-09
- **Final completion:** 2018-09
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Due to VTI-208 results, the ELAD clinical plan is being re-evaluated.
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01875874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01875874, "Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01875874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*